{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:09:23Z","timestamp":1789592963239,"version":"build-2803163510"},"reference-count":283,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.addr.2014.11.004","type":"journal-article","created":{"date-parts":[[2014,11,12]],"date-time":"2014-11-12T10:02:36Z","timestamp":1415786556000},"page":"65-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"special_numbering":"C","title":["Inhaled anti-infective chemotherapy for respiratory tract infections: Successes, challenges and the road ahead"],"prefix":"10.1016","volume":"85","author":[{"given":"Tony","family":"Velkov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nusaibah","family":"Abdul Rahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi (Tony)","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hak-Kim","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2014.11.004_bb0005","series-title":"Acute Respiratory Infections Atlas","author":"Schluger","year":"2010"},{"key":"10.1016\/j.addr.2014.11.004_bb0010","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/BF02718160","article-title":"Economic and long-term benefits of ribavirin therapy on respiratory syncytial virus infection","volume":"168","author":"Snell","year":"1990","journal-title":"Lung"},{"key":"10.1016\/j.addr.2014.11.004_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4269\/ajtmh.1986.35.1","article-title":"Acute respiratory infections are the leading cause of death in children in developing countries","volume":"35","author":"Denny","year":"1986","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.addr.2014.11.004_bb0020","doi-asserted-by":"crossref","first-page":"5086","DOI":"10.1016\/j.vaccine.2007.03.046","article-title":"The annual impact of seasonal influenza in the US: measuring disease burden and costs","volume":"25","author":"Molinari","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2014.11.004_bb0025","series-title":"Rapporteurs; Forum on microbial threats, microbial evolution and Co-adaptation: a tribute to the life and scientific legacies of Joshua Lederberg","author":"Relman","year":"2009"},{"key":"10.1016\/j.addr.2014.11.004_bb0030","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.addr.2013.07.020","article-title":"Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases","volume":"65","author":"Andrade","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2014.11.004_bb0035","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2014.03.006","article-title":"Emerging inhalation aerosol devices and strategies: where are we headed?","volume":"75","author":"Zhou","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2014.11.004_bb0040","article-title":"Inhaled formulations and pulmonary drug delivery systems for respiratory infections","author":"Zhou","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2014.11.004_bb0045","doi-asserted-by":"crossref","first-page":"156","DOI":"10.4065\/mcp.2010.0639","article-title":"General principles of antimicrobial therapy","volume":"86","author":"Leekha","year":"2011","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.addr.2014.11.004_bb0050","doi-asserted-by":"crossref","first-page":"658","DOI":"10.4187\/aarc0537","article-title":"Aerosol antibiotics in cystic fibrosis","volume":"54","author":"Geller","year":"2009","journal-title":"Respir. Care"},{"key":"10.1016\/j.addr.2014.11.004_bb0055","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/thx.53.9.732","article-title":"Long-term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis","volume":"53","author":"Ballmann","year":"1998","journal-title":"Thorax"},{"key":"10.1016\/j.addr.2014.11.004_bb0060","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1517\/17425247.3.1.71","article-title":"Aerosolised antibiotics: a critical appraisal of their use","volume":"3","author":"Hagerman","year":"2006","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2014.11.004_bb0065","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.2174\/156802610793176684","article-title":"Development of aminoglycoside antibiotics effective against resistant bacterial strains","volume":"10","author":"Yang","year":"2010","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.addr.2014.11.004_bb0070","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1445-5994.2011.02452.x","article-title":"Current use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity","volume":"41","author":"Avent","year":"2011","journal-title":"Intern. Med. J."},{"key":"10.1016\/j.addr.2014.11.004_bb0075","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1128\/AAC.49.2.479-487.2005","article-title":"Aminoglycoside resistance in Pseudomonas aeruginosa","volume":"49","author":"Poole","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb0080","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1177\/1753465811398267","article-title":"New and investigational treatments in cystic fibrosis","volume":"5","author":"Narasimhan","year":"2011","journal-title":"Ther. Adv. Respir. Dis."},{"key":"10.1016\/j.addr.2014.11.004_bb0085","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJM199901073400104","article-title":"Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group","volume":"340","author":"Ramsey","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2014.11.004_bb0090","series-title":"Australian Medicines Handbook","year":"2014"},{"key":"10.1016\/j.addr.2014.11.004_bb1420","series-title":"Electronic Medicines Compendium (eMC): Summary of Product Characteristics","article-title":"Tobi 300mg\/5ml Nebuliser Solution","year":"2013"},{"key":"10.1016\/j.addr.2014.11.004_bb0100","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1378\/chest.122.1.219","article-title":"Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis","volume":"122","author":"Geller","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.addr.2014.11.004_bb0105","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/ki.2010.337","article-title":"New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view","volume":"79","author":"Lopez-Novoa","year":"2011","journal-title":"Kidney Int."},{"key":"10.1016\/j.addr.2014.11.004_bb0110","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.tox.2008.04.015","article-title":"Aminoglycoside induced ototoxicity","volume":"249","author":"Guthrie","year":"2008","journal-title":"Toxicology"},{"key":"10.1016\/j.addr.2014.11.004_bb0115","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/ppul.21521","article-title":"Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution","volume":"47","author":"Sawicki","year":"2012","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.addr.2014.11.004_bb1425","series-title":"Bramitob\u00ae 300mg\/4ml Nebuliser Solution (tobramycin)","article-title":"Product Information","year":"2013"},{"key":"10.1016\/j.addr.2014.11.004_bb1430","series-title":"Electronic Medicines Compendium (eMC): Summary of Product Characteristics","article-title":"Bramitob Nebuliser Solution","year":"2013"},{"key":"10.1016\/j.addr.2014.11.004_bb0130","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.pupt.2012.12.002","article-title":"Pharmacokinetic and tolerability profiles of tobramycin nebuliser solution 300mg\/4ml administered by PARI eFlow\u00ae rapid and PARI LC Plus\u00ae nebulisers in cystic fibrosis patients","volume":"26","author":"Govoni","year":"2013","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2014.11.004_bb0135","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/clpt.2014.27","article-title":"Advances in inhaled technologies: understanding the therapeutic challenge, predicting clinical performance, and designing the optimal inhaled product","volume":"95","author":"Backman","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2014.11.004_bb0140","first-page":"179","article-title":"Tobramycin administered by the TOBI\u00ae Podhaler\u00ae for persons with cystic fibrosis: a review","volume":"4","author":"Vandevanter","year":"2011","journal-title":"Med. Devices (Auckl.)"},{"key":"10.1016\/j.addr.2014.11.004_bb0145","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1378\/chest.124.1.360","article-title":"Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers","volume":"124","author":"Newhouse","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.addr.2014.11.004_bb0150","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/ppul.20594","article-title":"Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety","volume":"42","author":"Geller","year":"2007","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.addr.2014.11.004_bb0155","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/ppul.21356","article-title":"Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial","volume":"46","author":"Konstan","year":"2011","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.addr.2014.11.004_bb0160","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jcf.2010.10.003","article-title":"Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial","volume":"10","author":"Konstan","year":"2011","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.addr.2014.11.004_bb0165","series-title":"FDA Anti-Infective Drugs Advisory Commitee","article-title":"TOBI\u00ae Podhaler\u2122 (Tobramycin Inhalation Powder 28mg capsules) For the management of cystic fibrosis patients with Pseudomonas aeruginosa","year":"2012"},{"key":"10.1016\/j.addr.2014.11.004_bb0170","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1128\/AAC.39.1.34","article-title":"Macromolecular mechanisms of sputum inhibition of tobramycin activity","volume":"39","author":"Hunt","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb0175","first-page":"761","article-title":"Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum","volume":"132","author":"Mendelman","year":"1985","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.addr.2014.11.004_bb0180","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1001\/archpediatrics.2011.136","article-title":"Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis","volume":"165","author":"Treggiari","year":"2011","journal-title":"Arch. Pediatr. Adolesc. Med."},{"key":"10.1016\/j.addr.2014.11.004_bb0185","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1164\/rccm.200208-855OC","article-title":"Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis","volume":"167","author":"Gibson","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2014.11.004_bb0190","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/thx.2009.121657","article-title":"Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial","volume":"65","author":"Ratjen","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.addr.2014.11.004_bb0195","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1513\/AnnalsATS.201311-395FR","article-title":"Inhaled antibiotics for lower airway infections","volume":"11","author":"Quon","year":"2014","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.addr.2014.11.004_bb0200","first-page":"CD008319","article-title":"Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis","volume":"12","author":"Ryan","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.addr.2014.11.004_bb0205","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1378\/chest.130.5.1503","article-title":"Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis","volume":"130","author":"Bilton","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.addr.2014.11.004_bb0210","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1164\/ajrccm.162.2.9910086","article-title":"Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis","volume":"162","author":"Barker","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2014.11.004_bb0215","doi-asserted-by":"crossref","first-page":"114S","DOI":"10.1378\/chest.120.3_suppl.114S","article-title":"Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa","volume":"120","author":"Couch","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.addr.2014.11.004_bb0220","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1345\/aph.1E099","article-title":"Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa","volume":"39","author":"Drobnic","year":"2005","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.addr.2014.11.004_bb0225","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1183\/09031936.00018414","article-title":"Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review","volume":"44","author":"Brodt","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.addr.2014.11.004_bb0230","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1128\/AAC.34.2.269","article-title":"Double-blind study of endotracheal tobramycin in the treatment of gram-negative bacterial pneumonia. The Endotracheal Tobramycin Study Group","volume":"34","author":"Brown","year":"1990","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb0235","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1089\/sur.2006.051","article-title":"Aerosolized tobramycin in the treatment of ventilator-associated pneumonia: a pilot study","volume":"8","author":"Hallal","year":"2007","journal-title":"Surg. Infect. (Larchmt.)"},{"key":"10.1016\/j.addr.2014.11.004_bb0240","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1055\/s-2007-998870","article-title":"Prevention of pneumonia by endotracheal micronebulization of tobramycin","volume":"28","author":"Rathgeber","year":"1993","journal-title":"Anasthesiol. Intensivmed. Notfallmed. Schmerzther."},{"key":"10.1016\/j.addr.2014.11.004_bb0245","first-page":"236","article-title":"Inhaled antibiotics in mechanically ventilated patients","volume":"80","author":"Michalopoulos","year":"2014","journal-title":"Minerva Anestesiol."},{"key":"10.1016\/j.addr.2014.11.004_bb0250","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s12325-008-0105-2","article-title":"Tobramycin nebulizer solution in severe COPD patients colonized with Pseudomonas aeruginosa: effects on bronchial inflammation","volume":"25","author":"Dal Negro","year":"2008","journal-title":"Adv. Ther."},{"key":"10.1016\/j.addr.2014.11.004_bb0255","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0025-7125(16)30036-0","article-title":"Aztreonam","volume":"79","author":"Johnson","year":"1995","journal-title":"Med. Clin. North Am."},{"key":"10.1016\/j.addr.2014.11.004_bb0260","first-page":"123","article-title":"Clinical perspective on aztreonam lysine for inhalation in patients with cystic fibrosis","volume":"3","author":"Daddario","year":"2010","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.addr.2014.11.004_bb0265","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1164\/rccm.200712-1804OC","article-title":"Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis","volume":"178","author":"McCoy","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2014.11.004_bb0270","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1378\/chest.08-1421","article-title":"Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis","volume":"135","author":"Retsch-Bogart","year":"2009","journal-title":"Chest"},{"issue":"Suppl. 2","key":"10.1016\/j.addr.2014.11.004_bb0275","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0954-6111(11)70021-X","article-title":"Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics","volume":"105","author":"Ballmann","year":"2011","journal-title":"Respir. Med."},{"key":"10.1016\/j.addr.2014.11.004_bb0280","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/ppul.20429","article-title":"Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis","volume":"41","author":"Gibson","year":"2006","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.addr.2014.11.004_bb0285","series-title":"CAYSTON\u00ae (aztreonam for inhalation solution)","article-title":"Product Monograph","year":"2012"},{"key":"10.1016\/j.addr.2014.11.004_bb0290","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1517\/14656566.2013.831070","article-title":"Inhaled aztreonam lysine: an evidence-based review","volume":"14","author":"Hutchinson","year":"2013","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.addr.2014.11.004_bb0295","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.2165\/10484070-000000000-00000","article-title":"Aztreonam lysine for inhalation solution: in cystic fibrosis","volume":"70","author":"Plosker","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2014.11.004_bb0300","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/ppul.21301","article-title":"An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis","volume":"45","author":"Oermann","year":"2010","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.addr.2014.11.004_bb0305","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jcf.2012.07.006","article-title":"Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial","volume":"12","author":"Assael","year":"2012","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.addr.2014.11.004_bb0310","author":"G. Sciences"},{"key":"10.1016\/j.addr.2014.11.004_bb0315","article-title":"Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: the ALPINE study","author":"Tiddens","year":"2014","journal-title":"J. Cyst. Fibros."},{"issue":"Suppl. 57","key":"10.1016\/j.addr.2014.11.004_bb0320","first-page":"P4136","article-title":"Two phase 3 placebo-controlled trials of Aztreonam Lysine for Inhalation (AZLI) for Non-Cystic Fibrosis Bronchiectasis (NCFB)","volume":"42","author":"Barker","year":"2013","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.addr.2014.11.004_bb0325","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1473-3099(06)70580-1","article-title":"Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections","volume":"6","author":"Li","year":"2006","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.addr.2014.11.004_bb0330","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1128\/AAC.00035-06","article-title":"Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa","volume":"50","author":"Bergen","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb0335","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/cid\/cit680","article-title":"Consistent global approach on reporting of colistin doses to promote safe and effective use","volume":"58","author":"Nation","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.addr.2014.11.004_bb0340","series-title":"Promixin, Powder for Nebuliser Solution","author":"Profile Pharma limited","year":"2010"},{"key":"10.1016\/j.addr.2014.11.004_bb0345","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1034\/j.1399-3003.2000.16d30.x","article-title":"Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus","volume":"16","author":"Doring","year":"2000","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.addr.2014.11.004_bb0350","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/0300-2977(95)00020-N","article-title":"Isolation and treatment of cystic fibrosis patients with lung infections caused by Pseudomonas (Burkholderia) cepacia and multiresistant Pseudomonas aeruginosa","volume":"46","author":"Hoiby","year":"1995","journal-title":"Neth. J. Med."},{"key":"10.1016\/j.addr.2014.11.004_bb0355","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1093\/jac\/19.6.831","article-title":"Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection","volume":"19","author":"Jensen","year":"1987","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb0360","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1183\/09031936.02.00248102","article-title":"A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis","volume":"20","author":"Hodson","year":"2002","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.addr.2014.11.004_bb0365","doi-asserted-by":"crossref","first-page":"5087","DOI":"10.1128\/AAC.01127-13","article-title":"Population pharmacokinetics of colistin methanesulfonate in rats: achieving sustained lung concentrations of colistin for targeting respiratory infections","volume":"57","author":"Yapa","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb0370","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1093\/jac\/dkr239","article-title":"Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006\u201309)","volume":"66","author":"Gales","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb0375","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/jac\/dki461","article-title":"Pharmacokinetics of inhaled colistin in patients with cystic fibrosis","volume":"57","author":"Ratjen","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb0380","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/jac\/dkg468","article-title":"Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis","volume":"52","author":"Li","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb0385","series-title":"TADIM\u00ae (colistimethate sodium)","article-title":"Product Information","year":"2013"},{"key":"10.1016\/j.addr.2014.11.004_bb0390","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jcf.2006.10.010","article-title":"Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study","volume":"6","author":"Westerman","year":"2007","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.addr.2014.11.004_bb0395","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1128\/AAC.00103-08","article-title":"Stability of colistin methanesulfonate in pharmaceutical products and solutions for administration to patients","volume":"52","author":"Wallace","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb0400","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ijpharm.2010.04.032","article-title":"Improving aerosolization of drug powders by reducing powder intrinsic cohesion via a mechanical dry coating approach","volume":"394","author":"Zhou","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2014.11.004_bb0405","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1208\/s12249-012-9895-z","article-title":"Effect of surface coating with magnesium stearate via mechanical dry powder coating approach on the aerosol performance of micronized drug powders from dry powder inhalers","volume":"14","author":"Zhou","year":"2013","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.addr.2014.11.004_bb0410","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1002\/jps.23685","article-title":"Colistin powders with high aerosolisation efficiency for respiratory infection: preparation and in vitro evaluation","volume":"102","author":"Zhou","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2014.11.004_bb0415","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/thoraxjnl-2012-202059","article-title":"Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study","volume":"68","author":"Schuster","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.addr.2014.11.004_bb0420","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1093\/jac\/dkq360","article-title":"Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria","volume":"65","author":"Rattanaumpawan","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb0425","doi-asserted-by":"crossref","first-page":"R123","DOI":"10.1186\/cc5032","article-title":"Administration of antibiotics via the respiratory tract for the prevention of ICU-acquired pneumonia: a meta-analysis of comparative trials","volume":"10","author":"Falagas","year":"2006","journal-title":"Crit. Care"},{"key":"10.1016\/j.addr.2014.11.004_bb0430","first-page":"73","article-title":"Inhaled liposomal ciprofloxacin: once a day management of respiratory infections","volume":"1","author":"Bruinenberg","year":"2010","journal-title":"Respir. Drug Deliv."},{"key":"10.1016\/j.addr.2014.11.004_bb0435","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1136\/thoraxjnl-2013-203207","article-title":"Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial","volume":"68","author":"Serisier","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.addr.2014.11.004_bb0440","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1183\/09031936.00071312","article-title":"Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study","volume":"41","author":"Wilson","year":"2013","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.addr.2014.11.004_bb0445","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1128\/AAC.02555-13","article-title":"Liposome encapsulation of ciprofloxacin improves protection against highly virulent Francisella tularensis strain Schu S4","volume":"58","author":"Hamblin","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb0450","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1164\/rccm.201008-1293OC","article-title":"Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa","volume":"183","author":"Geller","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2014.11.004_bb0455","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1128\/AAC.00248-09","article-title":"In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis","volume":"54","author":"King","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb0460","first-page":"A3037","article-title":"A phase 2 study to evaluate the safety, tolerability and efficacy of levofloxacin inhalation solution (MP-376) administered for 5days every 28days to prevent acute exacerbations in high risk COPD patients","volume":"185","author":"Sethi","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2014.11.004_bb0465","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/thoraxjnl-2012-202230","article-title":"Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection","volume":"68","author":"Clancy","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.addr.2014.11.004_bb0470","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/jac\/dkn059","article-title":"Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections","volume":"61","author":"Meers","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb0475","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2014.11.004_bb0480","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1513\/AnnalsATS.201307-231OC","article-title":"Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease","volume":"11","author":"Olivier","year":"2014","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.addr.2014.11.004_bb0485","author":"Insmed"},{"key":"10.1016\/j.addr.2014.11.004_bb0490","series-title":"Protocol Number: TR02-107","article-title":"A placebo controlled, randomized, parallel cohort, safety and tolerability study of two dose levels of liposomal amikacin for inhalation (Arikace\u2122) in patients with bronchiectasis complicated by chronic infection due to Pseudomonas aeruginosa","year":"2009"},{"key":"10.1016\/j.addr.2014.11.004_bb0495","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1164\/rccm.201011-1894OC","article-title":"Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa","volume":"184","author":"Lu","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2014.11.004_bb0500","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/jac\/dkp282","article-title":"Antibacterial activities of a fosfomycin\/tobramycin combination: a novel inhaled antibiotic for bronchiectasis","volume":"64","author":"MacLeod","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb0505","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1164\/rccm.201105-0924OC","article-title":"Fosfomycin\/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection","volume":"185","author":"Trapnell","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2014.11.004_bb0510","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1128\/AAC.40.1.186","article-title":"Pharmacokinetics of vancomycin in adult cystic fibrosis patients","volume":"40","author":"Pleasants","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb0515","author":"Synteract Inc"},{"key":"10.1016\/j.addr.2014.11.004_bb0520","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3109\/01902148.2011.632063","article-title":"Aerosolized clindamycin is superior to aerosolized dexamethasone or clindamycin-dexamethasone combination in the treatment of severe Porphyromonas gingivalis aspiration pneumonia in an experimental murine model","volume":"38","author":"Nemec","year":"2012","journal-title":"Exp. Lung Res."},{"key":"10.1016\/j.addr.2014.11.004_bb0525","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ijpharm.2012.01.026","article-title":"Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells","volume":"426","author":"Aquino","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2014.11.004_bb0530","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1089\/jamp.2011.0894","article-title":"Aerosol-based efficient delivery of clarithromycin, a macrolide antimicrobial agent, to lung epithelial lining fluid and alveolar macrophages for treatment of respiratory infections","volume":"25","author":"Togami","year":"2012","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2014.11.004_bb0535","doi-asserted-by":"crossref","first-page":"861","DOI":"10.3109\/03639040903551319","article-title":"Aerosol-based efficient delivery of telithromycin, a ketolide antimicrobial agent, to lung epithelial lining fluid and alveolar macrophages for treatment of respiratory infections","volume":"36","author":"Togami","year":"2010","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.addr.2014.11.004_bb0540","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1089\/jamp.2011.0925","article-title":"Adapting the Abbreviated Impactor Measurement (AIM) concept to make appropriate inhaler aerosol measurements to compare with clinical data: a scoping study with the \u201cAlberta\u201d idealized throat (AIT) inlet","volume":"25","author":"Mitchell","year":"2012","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2014.11.004_bb0545","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4155\/tde.13.71","article-title":"Liposomal formulations for inhalation","volume":"4","author":"Cipolla","year":"2013","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.addr.2014.11.004_bb0550","first-page":"653","article-title":"An open-label trial to investigate the dose delivery and tolerability of inhaled dry powder mannitol using the low output and high output orbital inhalers across defined flow rates in healthy volunteers","volume":"3","author":"Phillips","year":"2012","journal-title":"Respir. Drug Deliv."},{"key":"10.1016\/j.addr.2014.11.004_bb0555","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/1465-9921-6-144","article-title":"The safety and efficacy of inhaled dry powder mannitol as a bronchial provocation test for airway hyperresponsiveness: a phase 3 comparison study with hypertonic (4.5%) saline","volume":"6","author":"Brannan","year":"2005","journal-title":"Respir. Res."},{"key":"10.1016\/j.addr.2014.11.004_bb0560","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00001432-200304000-00010","article-title":"Pseudomonas aeruginosa pneumonia","volume":"16","author":"Garau","year":"2003","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.addr.2014.11.004_bb0565","series-title":"Methods for identifying a default cross-species scaling factor","author":"Rhomberg","year":"2004"},{"key":"10.1016\/j.addr.2014.11.004_bb0570","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.cll.2004.03.009","article-title":"Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections","volume":"24","author":"Andes","year":"2004","journal-title":"Clin. Lab. Med."},{"key":"10.1016\/j.addr.2014.11.004_bb0575","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1248\/bpb.b12-00407","article-title":"A rat model for stable chronic obstructive pulmonary disease induced by cigarette smoke inhalation and repetitive bacterial infection","volume":"35","author":"Li","year":"2012","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.addr.2014.11.004_bb0580","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/jac\/dkr567","article-title":"Prophylactic efficacy of single dose pulmonary administration of amphotericin B inhalation powder in a guinea pig model of invasive pulmonary aspergillosis","volume":"67","author":"Kirkpatrick","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb0585","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1023\/A:1013078330485","article-title":"Liquid dose pulmonary instillation of gentamicin PulmoSpheres formulations: tissue distribution and pharmacokinetics in rabbits","volume":"18","author":"Smith","year":"2001","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2014.11.004_bb0590","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1177\/019262330002800514","article-title":"Inhalation studies in laboratory animals\u2014current concepts and alternatives","volume":"28","author":"Pauluhn","year":"2000","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.addr.2014.11.004_bb0595","first-page":"S70","article-title":"Ribavirin therapy for respiratory syncytial virus infections. A scientific workshop. Long Beach, California, September 26\u201327, 1989","volume":"9","year":"1990","journal-title":"Proc. Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.addr.2014.11.004_bb0600","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1542\/peds.79.3.475","article-title":"American Academy of Pediatrics Committee on Infectious Diseases: Ribavirin therapy of respiratory syncytial virus","volume":"79","year":"1987","journal-title":"Pediatrics"},{"key":"10.1016\/j.addr.2014.11.004_bb0605","first-page":"45","article-title":"Management strategies for respiratory syncytial virus infections in infants","volume":"135","author":"Rodriguez","year":"1999","journal-title":"J. Pediatr."},{"key":"10.1016\/j.addr.2014.11.004_bb0610","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/archpedi.1986.02140180065025","article-title":"Vapors, viruses, and views. Ribavirin and respiratory syncytial virus","volume":"140","author":"Hall","year":"1986","journal-title":"Am. J. Dis. Child."},{"key":"10.1016\/j.addr.2014.11.004_bb0615","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1128\/AAC.25.1.53","article-title":"Combined interferon-alpha 2, rimantadine hydrochloride, and ribavirin inhibition of influenza virus replication in vitro","volume":"25","author":"Hayden","year":"1984","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb0620","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0166-3542(85)90012-9","article-title":"Mode of action of ribavirin: effect of nucleotide pool alterations on influenza virus ribonucleoprotein synthesis","volume":"5","author":"Wray","year":"1985","journal-title":"Antiviral Res."},{"key":"10.1016\/j.addr.2014.11.004_bb0625","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1128\/JVI.79.3.1943-1947.2005","article-title":"The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase","volume":"79","author":"Leyssen","year":"2005","journal-title":"J. Virol."},{"issue":"Suppl. 7","key":"10.1016\/j.addr.2014.11.004_bb0630","first-page":"459","article-title":"Antiviral mechanism of ribavirin against RNA virus","volume":"62","author":"Hamano","year":"2004","journal-title":"Nihon Rinsho"},{"key":"10.1016\/j.addr.2014.11.004_bb0635","first-page":"10","article-title":"Ribavirin as an antiviral agent: chemistry, molecular mechanism of action and possibilities of use (review)","volume":"32","author":"Galegov","year":"1986","journal-title":"Vopr. Med. Khim."},{"key":"10.1016\/j.addr.2014.11.004_bb0640","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0022-3476(94)70026-5","article-title":"High-dose, short-duration ribavirin aerosol therapy compared with standard ribavirin therapy in children with suspected respiratory syncytial virus infection","volume":"125","author":"Englund","year":"1994","journal-title":"J. Pediatr."},{"key":"10.1016\/j.addr.2014.11.004_bb0645","first-page":"180","article-title":"Ribavirin therapy of respiratory syncytial virus infections","volume":"107","author":"Ameratunga","year":"1994","journal-title":"N. Z. Med. J."},{"key":"10.1016\/j.addr.2014.11.004_bb0650","first-page":"1","article-title":"Respiratory syncytial virus and ribavirin therapy: winter 1987\u2013spring 1988. A report of 74 cases treated at Providence Hospital, Anchorage, Alaska","volume":"32","author":"Lyon","year":"1990","journal-title":"Alaska Med."},{"key":"10.1016\/j.addr.2014.11.004_bb0655","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/00006454-198511000-00014","article-title":"Ribavirin: beginning the blitz on respiratory viruses?","volume":"4","author":"Hall","year":"1985","journal-title":"Pediatr. Infect. Dis."},{"key":"10.1016\/j.addr.2014.11.004_bb0660","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1001\/jama.1985.03360210063030","article-title":"Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease","volume":"254","author":"Hall","year":"1985","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2014.11.004_bb0665","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1056\/NEJM198306163082403","article-title":"Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study","volume":"308","author":"Hall","year":"1983","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2014.11.004_bb0670","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1001\/jama.1983.03330430042027","article-title":"Ribavirin treatment of experimental respiratory syncytial viral infection. A controlled double-blind study in young adults","volume":"249","author":"Hall","year":"1983","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2014.11.004_bb0675","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0022-3476(05)80554-2","article-title":"High-dose, short-duration ribavirin aerosol therapy in children with suspected respiratory syncytial virus infection","volume":"117","author":"Englund","year":"1990","journal-title":"J. Pediatr."},{"key":"10.1016\/j.addr.2014.11.004_bb0680","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/000992289603500709","article-title":"Reassessment of indications for ribavirin therapy in respiratory syncytial virus infection","volume":"35","author":"Steele","year":"1996","journal-title":"Clin. Pediatr. (Phila.)"},{"key":"10.1016\/j.addr.2014.11.004_bb0685","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S0022-3476(95)70434-5","article-title":"Cost of ribavirin therapy for respiratory syncytial virus infection","volume":"126","author":"Marquardt","year":"1995","journal-title":"J. Pediatr."},{"key":"10.1016\/j.addr.2014.11.004_bb0690","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1097\/00006454-199711000-00004","article-title":"Long term follow-up of children hospitalized with respiratory syncytial virus lower respiratory tract infection and randomly treated with ribavirin or placebo","volume":"16","author":"Long","year":"1997","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.addr.2014.11.004_bb0695","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0022-3476(05)83347-5","article-title":"Early ribavirin treatment of respiratory syncytial viral infection in high-risk children","volume":"117","author":"Groothuis","year":"1990","journal-title":"J. Pediatr."},{"key":"10.1016\/j.addr.2014.11.004_bb0700","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1128\/AAC.17.5.770","article-title":"Effects of ribavirin on respiratory syncytial virus in vitro","volume":"17","author":"Hruska","year":"1980","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb0705","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/00006454-198702000-00003","article-title":"Aerosolized ribavirin treatment of respiratory syncytial virus infection in infants hospitalized during an epidemic","volume":"6","author":"Conrad","year":"1987","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.addr.2014.11.004_bb0710","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1399-3046.2006.00607.x","article-title":"Long-term therapy with aerosolized ribavirin for parainfluenza 3 virus respiratory tract infection in an infant with severe combined immunodeficiency","volume":"11","author":"Stankova","year":"2007","journal-title":"Pediatr. Transplant."},{"key":"10.1016\/j.addr.2014.11.004_bb0715","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/sj.bmt.1703131","article-title":"Respiratory syncytial virus infections in autologous blood and marrow transplant recipients with breast cancer: combination therapy with aerosolized ribavirin and parenteral immunoglobulins","volume":"28","author":"Ghosh","year":"2001","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.addr.2014.11.004_bb0720","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/sj.bmt.1702228","article-title":"Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin","volume":"25","author":"Ghosh","year":"2000","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.addr.2014.11.004_bb0725","first-page":"393","article-title":"Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients","volume":"16","author":"Whimbey","year":"1995","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.addr.2014.11.004_bb0730","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/sj.bmt.1701091","article-title":"Respiratory syncytial virus infection in adult BMT recipients: effective therapy with short duration nebulised ribavirin","volume":"21","author":"McColl","year":"1998","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.addr.2014.11.004_bb0735","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/sj.bmt.1700752","article-title":"Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections","volume":"19","author":"Sparrelid","year":"1997","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.addr.2014.11.004_bb0740","first-page":"29","article-title":"Successful therapy with ribavirin of late onset respiratory syncytial virus pneumonitis complicating allogeneic bone transplantation","volume":"14","author":"Win","year":"1992","journal-title":"Clin. Lab. Haematol."},{"key":"10.1016\/j.addr.2014.11.004_bb0745","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1097\/00006454-199009001-00007","article-title":"Developmental toxicity and safety evaluations of ribavirin","volume":"9","author":"Johnson","year":"1990","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.addr.2014.11.004_bb0750","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJM199107043250105","article-title":"A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection","volume":"325","author":"Smith","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2014.11.004_bb0755","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1128\/AAC.34.4.668","article-title":"Exposure of health care workers to ribavirin during therapy for respiratory syncytial virus infections","volume":"34","author":"Bradley","year":"1990","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb0760","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1128\/AAC.17.4.642","article-title":"Amantadine and ribavirin aerosol treatment of influenza A and B infection in mice","volume":"17","author":"Wilson","year":"1980","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb0765","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1749-6632.1977.tb21959.x","article-title":"Aerosol therapy of influenza infections of mice and primates with rimantadine, ribavirin, and related compounds","volume":"284","author":"Stephen","year":"1977","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.addr.2014.11.004_bb0770","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1128\/AAC.10.3.549","article-title":"Therapeutic effects of ribavirin given by the intraperitoneal or aerosol route against influenza virus infections in mice","volume":"10","author":"Stephen","year":"1976","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb0775","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1128\/AAC.11.6.1069","article-title":"Response of influenza virus-infected mice to selected doses of ribavirin administered intraperitoneally or by aerosol","volume":"11","author":"Berendt","year":"1977","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb0780","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1128\/AAC.30.6.942","article-title":"Protection of mice from lethal influenza virus infection with high dose-short duration ribavirin aerosol","volume":"30","author":"Wyde","year":"1986","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb0785","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0166-3542(87)90029-5","article-title":"Efficacy of high dose-short duration ribavirin aerosol in the treatment of respiratory syncytial virus infected cotton rats and influenza B virus infected mice","volume":"7","author":"Wyde","year":"1987","journal-title":"Antiviral Res."},{"key":"10.1016\/j.addr.2014.11.004_bb0790","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1128\/AAC.35.7.1448","article-title":"Aerosol and intraperitoneal administration of ribavirin and ribavirin triacetate: pharmacokinetics and protection of mice against intracerebral infection with influenza A\/WSN virus","volume":"35","author":"Gilbert","year":"1991","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb0795","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0166-3542(92)90088-M","article-title":"Further studies with short duration ribavirin aerosol for the treatment of influenza virus infection in mice and respiratory syncytial virus infection in cotton rats","volume":"17","author":"Gilbert","year":"1992","journal-title":"Antiviral Res."},{"issue":"Suppl.","key":"10.1016\/j.addr.2014.11.004_bb0800","doi-asserted-by":"crossref","first-page":"A140","DOI":"10.1093\/infdis\/133.Supplement_2.A140","article-title":"Small-particle aerosols of antiviral compounds in treatment of type A influenza pneumonia in mice","volume":"133","author":"Walker","year":"1976","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2014.11.004_bb0805","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.antiviral.2008.01.005","article-title":"MegaRibavirin aerosol for the treatment of influenza A virus infections in mice","volume":"78","author":"Gilbert","year":"2008","journal-title":"Antiviral Res."},{"key":"10.1016\/j.addr.2014.11.004_bb0810","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1128\/AAC.27.3.309","article-title":"Ribavirin small-particle aerosol treatment of infections caused by influenza virus strains A\/Victoria\/7\/83 (H1N1) and B\/Texas\/1\/84","volume":"27","author":"Gilbert","year":"1985","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb0815","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1128\/AAC.26.2.200","article-title":"Treatment of influenza A (H1N1) virus infection with ribavirin aerosol","volume":"26","author":"Wilson","year":"1984","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb0820","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0891-5520(20)30119-7","article-title":"Ribavirin aerosol treatment of influenza","volume":"1","author":"Knight","year":"1987","journal-title":"Infect. Dis. Clin. North Am."},{"key":"10.1016\/j.addr.2014.11.004_bb0825","first-page":"284","article-title":"Ribavirin aerosol treatment of influenza B virus infection","volume":"96","author":"McClung","year":"1983","journal-title":"Trans. Assoc. Am. Physicians"},{"key":"10.1016\/j.addr.2014.11.004_bb0830","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(81)91152-1","article-title":"Ribavirin small-particle aerosol treatment of influenza","volume":"2","author":"Knight","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2014.11.004_bb0835","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0022-3476(94)70139-3","article-title":"Efficacy and safety of aerosolized ribavirin in young children hospitalized with influenza: a double-blind, multicenter, placebo-controlled trial","volume":"125","author":"Rodriguez","year":"1994","journal-title":"J. Pediatr."},{"key":"10.1016\/j.addr.2014.11.004_bb0840","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1128\/AAC.12.4.498","article-title":"Double-blind evaluation of oral ribavirin (Virazole) in experimental influenza A virus infection in volunteers","volume":"12","author":"Magnussen","year":"1977","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb0845","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1128\/AAC.32.5.761","article-title":"Ribavirin small-particle-aerosol treatment of influenza B virus infection","volume":"32","author":"Bernstein","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb0850","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMc0905290","article-title":"Use of ribavirin to treat influenza","volume":"361","author":"Chan-Tack","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2014.11.004_bb0855","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/jat.2550070509","article-title":"Inhalation toxicity of ribavirin in suckling ferrets","volume":"7","author":"Hoffmann","year":"1987","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.addr.2014.11.004_bb0860","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/135965359900400404","article-title":"Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1year of open-label experience. Ribavirin Study Group","volume":"4","author":"Chapman","year":"1999","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.addr.2014.11.004_bb0865","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/infdis\/164.6.1119","article-title":"Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome","volume":"164","author":"Huggins","year":"1991","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2014.11.004_bb0870","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.antiviral.2007.10.012","article-title":"Treatment of hantavirus pulmonary syndrome","volume":"78","author":"Jonsson","year":"2008","journal-title":"Antiviral Res."},{"key":"10.1016\/j.addr.2014.11.004_bb0875","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/363418a0","article-title":"Rational design of potent sialidase-based inhibitors of influenza virus replication","volume":"363","author":"von Itzstein","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.addr.2014.11.004_bb0880","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1126\/science.1232552","article-title":"Mechanism-based covalent neuraminidase inhibitors with broad-spectrum influenza antiviral activity","volume":"340","author":"Kim","year":"2013","journal-title":"Science"},{"issue":"Suppl. B","key":"10.1016\/j.addr.2014.11.004_bb0885","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/jac\/44.suppl_2.23","article-title":"Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis","volume":"44","author":"Monto","year":"1999","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb0890","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1086\/314904","article-title":"Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections","volume":"180","author":"Monto","year":"1999","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2014.11.004_bb0895","doi-asserted-by":"crossref","first-page":"10366","DOI":"10.1128\/JVI.01200-09","article-title":"Zanamivir-resistant influenza viruses with a novel neuraminidase mutation","volume":"83","author":"Hurt","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2014.11.004_bb0900","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.coviro.2011.09.002","article-title":"Antivirals and resistance: influenza virus","volume":"1","author":"Ison","year":"2011","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.addr.2014.11.004_bb0905","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/j.clinthera.2007.08.023","article-title":"Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial","volume":"29","author":"LaForce","year":"2007","journal-title":"Clin. Ther."},{"key":"10.1016\/j.addr.2014.11.004_bb0910","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1128\/AAC.44.7.1974-1976.2000","article-title":"Direct measurement of the anti-influenza agent zanamivir in the respiratory tract following inhalation","volume":"44","author":"Peng","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb0915","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1086\/315392","article-title":"Rapid antiviral effect of inhaled zanamivir in the treatment of naturally occurring influenza in otherwise healthy adults","volume":"181","author":"Boivin","year":"2000","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2014.11.004_bb0920","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1056\/NEJM200011023431801","article-title":"Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group","volume":"343","author":"Hayden","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2014.11.004_bb0925","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/00006454-200005000-00005","article-title":"Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial","volume":"19","author":"Hedrick","year":"2000","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.addr.2014.11.004_bb0930","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1001\/archinte.161.2.212","article-title":"Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials","volume":"161","author":"Lalezari","year":"2001","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.addr.2014.11.004_bb0935","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jinf.2007.09.002","article-title":"A comparison of the effectiveness of zanamivir and oseltamivir for the treatment of influenza A and B","volume":"56","author":"Kawai","year":"2008","journal-title":"J. Infect."},{"key":"10.1016\/j.addr.2014.11.004_bb0940","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3109\/00365548.2011.556144","article-title":"Failure of combination oral oseltamivir and inhaled zanamivir antiviral treatment in ventilator- and ECMO-treated critically ill patients with pandemic influenza A (H1N1)v","volume":"43","author":"Petersen","year":"2011","journal-title":"Scand. J. Infect. Dis."},{"key":"10.1016\/j.addr.2014.11.004_bb0945","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/135965350300800301","article-title":"Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza","volume":"8","author":"Ison","year":"2003","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.addr.2014.11.004_bb0950","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1086\/650176","article-title":"Fatal respiratory events caused by zanamivir nebulization","volume":"50","author":"Kiatboonsri","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.addr.2014.11.004_bb0955","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1056\/NEJM200003023420914","article-title":"Respiratory distress associated with zanamivir","volume":"342","author":"Williamson","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2014.11.004_bb0960","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/jamp.2010.0825","article-title":"Method to introduce mannitol powder to intubated patients to improve sputum clearance","volume":"24","author":"Tang","year":"2011","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2014.11.004_bb0965","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3851\/IMP1688","article-title":"Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza","volume":"21","author":"Yamashita","year":"2010","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb0970","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1128\/AAC.01755-09","article-title":"Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection","volume":"54","author":"Sugaya","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb0975","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1086\/656802","article-title":"Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, noninferiority clinical trial","volume":"51","author":"Watanabe","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.addr.2014.11.004_bb0980","doi-asserted-by":"crossref","first-page":"e92601","DOI":"10.1371\/journal.pone.0092601","article-title":"Effects of vaccination and the new neuraminidase inhibitor, laninamivir, on influenza infection","volume":"9","author":"Mizuno","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2014.11.004_bb0985","doi-asserted-by":"crossref","first-page":"e1431","DOI":"10.1542\/peds.2011-2054","article-title":"Effect of a single inhalation of laninamivir octanoate in children with influenza","volume":"129","author":"Katsumi","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.addr.2014.11.004_bb0990","series-title":"Biota Initiates Dosing in Phase 2 IGLOO Trial of LANI in the Northern Hemisphere","author":"Biota Pharmaceuticals, Inc.","year":"2013"},{"key":"10.1016\/j.addr.2014.11.004_bb0995","doi-asserted-by":"crossref","first-page":"524","DOI":"10.5694\/j.1326-5377.1990.tb125353.x","article-title":"Could preventive intranasal interferon lower the morbidity in children prone to respiratory illness?","volume":"152","author":"Douglas","year":"1990","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.addr.2014.11.004_bb1000","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1056\/NEJM198601093140201","article-title":"Prophylactic efficacy of intranasal alpha 2-interferon against rhinovirus infections in the family setting","volume":"314","author":"Douglas","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2014.11.004_bb1005","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/infdis\/151.4.731","article-title":"Intranasal interferon-alpha 2 prophylaxis of natural respiratory virus infection","volume":"151","author":"Douglas","year":"1985","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2014.11.004_bb1010","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S0140-6736(83)90470-1","article-title":"Intranasal interferon for contact prophylaxis against common cold in families","volume":"2","author":"Herzog","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2014.11.004_bb1015","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1089\/jir.1984.4.535","article-title":"Intranasal lymphoblastoid interferon (\u201cWellferon\u201d) prophylaxis against rhinovirus and influenza virus in volunteers","volume":"4","author":"Phillpotts","year":"1984","journal-title":"J. Interferon Res."},{"key":"10.1016\/j.addr.2014.11.004_bb1020","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(82)91031-5","article-title":"Prevention of rhinovirus colds by human interferon alpha-2 from Escherichia coli","volume":"2","author":"Scott","year":"1982","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2014.11.004_bb1025","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0140-6736(73)90714-9","article-title":"Inhibition of respiratory virus infection by locally applied interferon","volume":"1","author":"Merigan","year":"1973","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2014.11.004_bb1030","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1128\/AAC.26.1.31","article-title":"Intranasal interferon-alpha 2 for prevention of natural rhinovirus colds","volume":"26","author":"Farr","year":"1984","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb1035","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1136\/bmj.284.6332.1822","article-title":"Purified interferon as protection against rhinovirus infection","volume":"284","author":"Scott","year":"1982","journal-title":"Br. Med. J. (Clin. Res. Ed)"},{"key":"10.1016\/j.addr.2014.11.004_bb1040","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1136\/adc.69.4.440","article-title":"Treatment of respiratory syncytial virus infection with recombinant interferon alfa-2a","volume":"69","author":"Sung","year":"1993","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.addr.2014.11.004_bb1045","first-page":"162","article-title":"Children's respiratory viral diseases treated with interferon aerosol","volume":"100","author":"Dai","year":"1987","journal-title":"Chin. Med. J. (Engl)"},{"key":"10.1016\/j.addr.2014.11.004_bb1050","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/infdis\/150.2.181","article-title":"Intranasally applied recombinant leukocyte A interferon in normal volunteers. II. Determination of minimal effective and tolerable dose","volume":"150","author":"Samo","year":"1984","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2014.11.004_bb1055","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/infdis\/148.3.543","article-title":"Intranasal interferon alpha 2 for prevention of rhinovirus infection and illness","volume":"148","author":"Hayden","year":"1983","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2014.11.004_bb1060","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0166-3542(87)90067-2","article-title":"Tolerance and nasal histopathologic effects of long-term, low-dose intranasal recombinant interferon alpha-2A (Roferon-A)","volume":"8","author":"Hayden","year":"1987","journal-title":"Antiviral Res."},{"key":"10.1016\/j.addr.2014.11.004_bb1065","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/infdis\/148.5.914","article-title":"Human tolerance and histopathologic effects of long-term administration of intranasal interferon-alpha 2","volume":"148","author":"Hayden","year":"1983","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2014.11.004_bb1070","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/infdis\/148.3.535","article-title":"Efficacy and tolerance of intranasally applied recombinant leukocyte A interferon in normal volunteers","volume":"148","author":"Samo","year":"1983","journal-title":"J. Infect. Dis."},{"issue":"Suppl. 1","key":"10.1016\/j.addr.2014.11.004_bb1075","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0166-3542(85)80033-4","article-title":"Clinical applications of antiviral agents for chemophrophylaxis and therapy of respiratory viral infections","author":"Hayden","year":"1985","journal-title":"Antiviral Res."},{"key":"10.1016\/j.addr.2014.11.004_bb1080","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1056\/NEJM198601093140202","article-title":"Prevention of natural colds by contact prophylaxis with intranasal alpha 2-interferon","volume":"314","author":"Hayden","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2014.11.004_bb1085","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1093\/infdis\/150.2.174","article-title":"Intranasal interferon-alpha 2 treatment of experimental rhinoviral colds","volume":"150","author":"Hayden","year":"1984","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2014.11.004_bb1090","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0166-3542(85)90037-3","article-title":"Prophylactic efficacy and tolerance of low-dose intranasal interferon-alpha 2 in natural respiratory viral infections","volume":"5","author":"Hayden","year":"1985","journal-title":"Antiviral Res."},{"key":"10.1016\/j.addr.2014.11.004_bb1095","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/infdis\/154.3.443","article-title":"Prevention of experimental coronavirus colds with intranasal alpha-2b interferon","volume":"154","author":"Turner","year":"1986","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2014.11.004_bb1100","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1164\/ajrccm\/148.6_Pt_1.1677","article-title":"The effects of inhaled interferon gamma in normal human airways","volume":"148","author":"Martin","year":"1993","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.addr.2014.11.004_bb1105","first-page":"75","article-title":"Inhaled natural human interferon alpha induces bronchospastic reactions in asthmatics","volume":"40","author":"Krasnowska","year":"1992","journal-title":"Arch. Immunol. Ther. Exp. (Warsz.)"},{"key":"10.1016\/j.addr.2014.11.004_bb1110","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1089\/jir.1989.9.419","article-title":"Pharmacokinetics and toxicity of inhaled human interferon-alpha in patients with lung cancer","volume":"9","author":"Kinnula","year":"1989","journal-title":"J. Interferon Res."},{"key":"10.1016\/j.addr.2014.11.004_bb1115","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1089\/jir.1982.2.127","article-title":"Interim report on studies on \u201ctoxic\u201d effects of human leucocyte-derived interferon-alpha (HuIFN-alpha)","volume":"2","author":"Scott","year":"1982","journal-title":"J. Interferon Res."},{"key":"10.1016\/j.addr.2014.11.004_bb1120","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/infdis\/156.1.64","article-title":"Human nasal mucosal responses to topically applied recombinant leukocyte A interferon","volume":"156","author":"Hayden","year":"1987","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2014.11.004_bb1125","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1128\/AAC.43.10.2444","article-title":"In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease","volume":"43","author":"Patick","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb1130","doi-asserted-by":"crossref","first-page":"11000","DOI":"10.1073\/pnas.96.20.11000","article-title":"Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes","volume":"96","author":"Matthews","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2014.11.004_bb1135","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0166-3542(00)00106-6","article-title":"In vitro activity of pleconaril and AG7088 against selected serotypes and clinical isolates of human rhinoviruses","volume":"47","author":"Kaiser","year":"2000","journal-title":"Antiviral Res."},{"key":"10.1016\/j.addr.2014.11.004_bb1140","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1128\/AAC.47.12.3907-3916.2003","article-title":"Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers","volume":"47","author":"Hayden","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb1145","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/15476910500203925","article-title":"Lack of respiratory and contact sensitizing potential of the intranasal antiviral drug candidate rupintrivir (AG7088): a weight-of-the-evidence evaluation","volume":"2","author":"Burns-Naas","year":"2005","journal-title":"J. Immunotoxicol."},{"key":"10.1016\/j.addr.2014.11.004_bb1150","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1128\/AAC.46.3.841-847.2002","article-title":"RFI-641, a potent respiratory syncytial virus inhibitor","volume":"46","author":"Huntley","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb1155","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0166-3542(98)00002-3","article-title":"CL387626 exhibits marked and unusual antiviral activity against respiratory syncytial virus in tissue culture and in cotton rats","volume":"38","author":"Wyde","year":"1998","journal-title":"Antiviral Res."},{"key":"10.1016\/j.addr.2014.11.004_bb1160","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0960-894X(01)00150-0","article-title":"The discovery of RFI-641 as a potent and selective inhibitor of the respiratory syncytial virus","volume":"11","author":"Nikitenko","year":"2001","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.addr.2014.11.004_bb1165","first-page":"425","article-title":"VP-14637 ViroPharma","volume":"1","author":"McKimm-Breschkin","year":"2000","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.addr.2014.11.004_bb1170","doi-asserted-by":"crossref","first-page":"5054","DOI":"10.1128\/JVI.77.9.5054-5064.2003","article-title":"Inhibition of respiratory syncytial virus fusion by the small molecule VP-14637 via specific interactions with F protein","volume":"77","author":"Douglas","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2014.11.004_bb1175","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.antiviral.2003.07.002","article-title":"Short duration aerosols of JNJ 2408068 (R170591) administered prophylactically or therapeutically protect cotton rats from experimental respiratory syncytial virus infection","volume":"60","author":"Wyde","year":"2003","journal-title":"Antiviral Res."},{"key":"10.1016\/j.addr.2014.11.004_bb1180","doi-asserted-by":"crossref","first-page":"4534","DOI":"10.1128\/AAC.00643-10","article-title":"Pharmacokinetics\u2013pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model","volume":"54","author":"Rouan","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb1185","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1183\/09031936.00005610","article-title":"Antiviral and lung protective activity of a novel respiratory syncytial virus fusion inhibitor in a mouse model","volume":"38","author":"Olszewska","year":"2011","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.addr.2014.11.004_bb1190","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1128\/AAC.48.2.413-422.2004","article-title":"Orally active fusion inhibitor of respiratory syncytial virus","volume":"48","author":"Cianci","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb1195","doi-asserted-by":"crossref","first-page":"15046","DOI":"10.1073\/pnas.0406696101","article-title":"Targeting a binding pocket within the trimer-of-hairpins: small-molecule inhibition of viral fusion","volume":"101","author":"Cianci","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2014.11.004_bb1200","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.2174\/138161209787846775","article-title":"Antiviral role of toll-like receptor-3 agonists against seasonal and avian influenza viruses","volume":"15","author":"Wong","year":"2009","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.addr.2014.11.004_bb1205","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1016\/j.vaccine.2007.01.051","article-title":"Nucleic acid-based antiviral drugs against seasonal and avian influenza viruses","volume":"25","author":"Wong","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2014.11.004_bb1210","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1016\/j.vaccine.2009.01.048","article-title":"Activation of toll-like receptor signaling pathway for protection against influenza virus infection","volume":"27","author":"Wong","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2014.11.004_bb1215","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.addr.2014.11.004_bb1220","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11908-008-0007-x","article-title":"Inhaled antimicrobial therapies for respiratory infections","volume":"10","author":"Kim","year":"2008","journal-title":"Curr. Infect. Dis. Rep."},{"key":"10.1016\/j.addr.2014.11.004_bb1225","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1056\/NEJM199009203231201","article-title":"Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. The San Francisco community prophylaxis trial","volume":"323","author":"Leoung","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2014.11.004_bb1230","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1378\/chest.95.4.747","article-title":"Aerosolized pentamidine as second line therapy in patients with AIDS and Pneumocystis carinii pneumonia","volume":"95","author":"Montgomery","year":"1989","journal-title":"Chest"},{"key":"10.1016\/j.addr.2014.11.004_bb1235","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/clinids\/20.3.531","article-title":"Once-weekly administration of dapsone\/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients","volume":"20","author":"Opravil","year":"1995","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.addr.2014.11.004_bb1240","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199503163321101","article-title":"A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group","volume":"332","author":"Bozzette","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2014.11.004_bb1245","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1056\/NEJM199212243272604","article-title":"A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021","volume":"327","author":"Hardy","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2014.11.004_bb1250","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJM199212243272603","article-title":"A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group","volume":"327","author":"Schneider","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2014.11.004_bb1255","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1086\/314893","article-title":"Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides","volume":"180","author":"Chan","year":"1999","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2014.11.004_bb1260","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1056\/NEJM199305273282102","article-title":"Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study Group","volume":"328","author":"Girard","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2014.11.004_bb1265","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1399-3062.2007.00209.x","article-title":"Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study","volume":"9","author":"Lowry","year":"2007","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.addr.2014.11.004_bb1270","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1111\/j.1600-6143.2006.01529.x","article-title":"Aerosol deposition of lipid complex amphotericin-B (Abelcet) in lung transplant recipients","volume":"6","author":"Corcoran","year":"2006","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.addr.2014.11.004_bb1275","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1211\/jpp.57.10.0007","article-title":"Nebulization of four commercially available amphotericin B formulations in persistently granulocytopenic rats with invasive pulmonary aspergillosis: evidence for long-term biological activity","volume":"57","author":"Ruijgrok","year":"2005","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.addr.2014.11.004_bb1280","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1128\/AAC.42.7.1597","article-title":"Pharmacokinetic evaluation of amphotericin B in lung tissue: lung lymph distribution after intravenous injection and airspace distribution after aerosolization and inhalation of amphotericin B","volume":"42","author":"Koizumi","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb1285","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1021\/js9604218","article-title":"Disposition of aerosolized liposomal amphotericin B","volume":"86","author":"Lambros","year":"1997","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2014.11.004_bb1290","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1183\/09031936.95.08081263","article-title":"Deposition of amphotericin B aerosols in pulmonary aspergilloma","volume":"8","author":"Diot","year":"1995","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.addr.2014.11.004_bb1295","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1128\/AAC.34.1.29","article-title":"Pharmacokinetics of aerosol amphotericin B in rats","volume":"34","author":"Niki","year":"1990","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb1300","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.healun.2008.11.004","article-title":"Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety","volume":"28","author":"Monforte","year":"2009","journal-title":"J. Heart Lung Transplant."},{"key":"10.1016\/j.addr.2014.11.004_bb1305","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1086\/586739","article-title":"Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial","volume":"46","author":"Rijnders","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.addr.2014.11.004_bb1310","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1016\/j.transproceed.2008.09.020","article-title":"Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation","volume":"40","author":"Borro","year":"2008","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.addr.2014.11.004_bb1315","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1053-2498(01)00364-3","article-title":"Nebulized amphotericin B prophylaxis for Aspergillus infection in lung transplantation: study of risk factors","volume":"20","author":"Monforte","year":"2001","journal-title":"J. Heart Lung Transplant."},{"key":"10.1016\/j.addr.2014.11.004_bb1320","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/BF01726364","article-title":"Tolerance and efficacy of Amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in haematological patients","volume":"16","author":"Erjavec","year":"1997","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.addr.2014.11.004_bb1325","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/BF01697981","article-title":"Aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in neutropenic cancer patients","volume":"71","author":"Behre","year":"1995","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.addr.2014.11.004_bb1330","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3109\/10428199209054909","article-title":"A pilot study of prophylactic aerosolized amphotericin B in patients at risk for prolonged neutropenia","volume":"8","author":"Myers","year":"1992","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.addr.2014.11.004_bb1335","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1136\/thx.54.11.1047","article-title":"Successful treatment of post-influenza pseudomembranous necrotising bronchial aspergillosis with liposomal amphotericin, inhaled amphotericin B, gamma interferon and GM-CSF","volume":"54","author":"Boots","year":"1999","journal-title":"Thorax"},{"key":"10.1016\/j.addr.2014.11.004_bb1340","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1097\/01.TP.0000054233.60100.7A","article-title":"Nebulized amphotericin B concentration and distribution in the respiratory tract of lung-transplanted patients","volume":"75","author":"Monforte","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.addr.2014.11.004_bb1345","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/BF01739026","article-title":"Use of amphotericin B aerosols for the prevention of pulmonary aspergillosis","volume":"22","author":"Beyer","year":"1994","journal-title":"Infection"},{"key":"10.1016\/j.addr.2014.11.004_bb1350","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1517\/14740338.6.5.523","article-title":"Safety of aerosolized amphotericin B","volume":"6","author":"Knechtel","year":"2007","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.addr.2014.11.004_bb1355","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.pupt.2008.09.001","article-title":"Tolerability of prophylactic aerosolized liposomal amphotericin-B and impact on pulmonary function: data from a randomized placebo-controlled trial","volume":"21","author":"Slobbe","year":"2008","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2014.11.004_bb1360","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00000421-199302000-00011","article-title":"The toxicity of daily inhaled amphotericin B","volume":"16","author":"Gryn","year":"1993","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.addr.2014.11.004_bb1365","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1183\/09031936.00163511","article-title":"Remarkably efficient inhaled antifungal monotherapy for invasive pulmonary aspergillosis","volume":"40","author":"Hilberg","year":"2012","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.addr.2014.11.004_bb1370","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1128\/AAC.01657-08","article-title":"Inhaled voriconazole for prevention of invasive pulmonary aspergillosis","volume":"53","author":"Tolman","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb1375","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijpharm.2009.06.003","article-title":"Dose tolerability of chronically inhaled voriconazole solution in rodents","volume":"379","author":"Tolman","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2014.11.004_bb1380","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ejpb.2008.12.014","article-title":"Characterization and pharmacokinetic analysis of aerosolized aqueous voriconazole solution","volume":"72","author":"Tolman","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2014.11.004_bb1385","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1128\/AAC.38.6.1397","article-title":"Aerosolized L-693,989 for Pneumocystis carinii prophylaxis in rats","volume":"38","author":"Powles","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb1390","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jinf.2007.01.014","article-title":"Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis","volume":"55","author":"Alvarez","year":"2007","journal-title":"J. Infect."},{"key":"10.1016\/j.addr.2014.11.004_bb1395","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1128\/AAC.50.4.1552-1554.2006","article-title":"In vivo efficacy of aerosolized nanostructured itraconazole formulations for prevention of invasive pulmonary aspergillosis","volume":"50","author":"Hoeben","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.11.004_bb1400","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1378\/chest.128.5.3711","article-title":"Suitability of caspofungin for aerosol delivery: physicochemical profiling and nebulizer choice","volume":"128","author":"Wong-Beringer","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.addr.2014.11.004_bb1405","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1006\/rtph.1997.1099","article-title":"Considerations for toxicology studies of respiratory drug products","volume":"25","author":"DeGeorge","year":"1997","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.addr.2014.11.004_bb1410","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40261-013-0082-0","article-title":"Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study","volume":"33","author":"Stass","year":"2013","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.addr.2014.11.004_bb1415","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.clinthera.2013.08.003","article-title":"Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study","volume":"35","author":"Stass","year":"2013","journal-title":"Clin. Ther."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X14002671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X14002671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T02:12:17Z","timestamp":1650593537000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X14002671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":283,"alternative-id":["S0169409X14002671"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2014.11.004","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhaled anti-infective chemotherapy for respiratory tract infections: Successes, challenges and the road ahead","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2014.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}